eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest

eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest
Daily treatment with a low dose of eRapa, Emtora Biosciences' new formulation of the therapeutic agent rapamycin, was safe and well tolerated, and led to immune system cell boosting in patients with low-grade prostate cancer, according to data from a Phase 1b clinical trial. The findings were presented in a poster at the 2020 Clinical Immuno-Oncology Symposium of the American Society of Clinical Oncology and Society for Immunotherapy of Cancer in Orlando, Florida. The study was titled, "Results of a phase Ib trial of encapsulated rapamycin in prostate cancer patients under active surveillance to prevent progression." Activation of mTOR — a protein kinase involved in cell proliferation and survival — has long been known to influence prostate cancer growth and metastasis, making it a promising target for cancer therapy. Rapamycin, a naturally occurring chemical that inhibits mTOR, and its analogs have been successfully applied to treat specific cancers in the clinic. But despite its potential, rapamycin has shown low bioavailability (the fraction of a therapy that actually reaches circulation) and toxicity, and pharmacokinetics (the way the body processes a therapy) varies among patients. eRapa, a proprietary formulation, was developed to improve rapamycin's properties. It consists of very small rapamycin particles enclosed in a polymer capsule that protects the therapy's active ingredient from degradation in the stomach's acidic environment. According to the company, eRapa provides nearly 30% more therapy than generic rapamycin, as well as less interpatient variation in terms of absorption, distribution, metabolism, and excretion. The Phase 1b clinical trial (NCT03618355) evaluated the safety and effectiveness of eRapa in patients with low-grade p
Subscribe or to access all post and page content.